News & Events

Press Releases

  • Year Published

GeneCentric Therapeutics Announces Commercial Availability of PurISTSM Test for Pancreatic Cancer

May 31, 2023
PurIST is an RNA expression-based test for pancreatic cancer molecular subtyping that can help inform and personalize cancer treatment Durham, N.C., May 31, 2023 – GeneCentric Therapeutics, a company making precision medicine…
Read More

GeneCentric Therapeutics Initiates the Alamance Study – A Real-World Investigation of Bladder Cancer Patients Treated with FGFR Inhibitors and Other Standards of Care

May 16, 2023
The Alamance study will evaluate a novel FGFR Predictive Response Signature in development to personalize cancer treatment Durham, N.C., May 16, 2023 – GeneCentric Therapeutics, a company making precision medicine more precise…
Read More

GeneCentric Therapeutics Appoints Brian Kelly as SVP Business Development

April 12, 2023
Durham, NC, April 12, 2023 –  GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced the appointment of Brian Kelly as Senior Vice President of Business Development. Mr.…
Read More

GeneCentric to Present Data on the Purity Independent Subtyping of Tumor (PurIST) Test at AACR Pancreatic Conference

September 13, 2022
Durham, NC, September 13, 2022 –  GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the poster presentation of further clinical validation data for PurISTSM, a novel RNA-expression…
Read More

GeneCentric Publishes New Data Comparing Predictive Immune Response Profiles in Patients Treated with Checkpoint Inhibition or IL-2

August 23, 2022
A novel RNA-based IL-2 treatment response classifier was developed as part of the study in patients with renal cell carcinoma Durham, NC, August 23, 2022 – GeneCentric Therapeutics, a company making precision…
Read More

GeneCentric to Present Initial Clinicogenomic Results from the GARNER High-Risk Non-Muscle Invasive Bladder Cancer Real-World Study

May 10, 2022
New HR-NMIBC molecular analyses to be presented at the 2022 AUA Annual Meeting Durham, NC, May 10, 2022 –  GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today…
Read More

Neil Hayes, GeneCentric co-founder, highlighted for his work and upcoming AACR presentation by UTHSC where he is the Director of the Center for Cancer Research

March 24, 2022
For two decades, scientists have been able to identify the molecular signature of specific cancers by isolating the RNA, responsible for dictating which proteins are produced and, by extension, how the cells…
Read More

GeneCentric to Present Discovery and Initial Clinical Utility of a Novel RNA-Based Gene Signature That Predicts Treatment Response in Patients with Head and Neck Cancer

March 17, 2022
New molecular analyses to be presented at the AACR Annual Meeting 2022 DURHAM, N.C.–(BUSINESS WIRE)– GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the upcoming oral…
Read More

GeneCentric Therapeutics Identifies RNA-Based Genomic Markers of Clinical Response in Lung Cancer

December 21, 2021
The Piedmont Study, a Real-World Data Analysis in Patients Treated with Platinum Doublet Chemotherapy and/or Pembrolizumab, Identifies Predictive Biomarkers for Approved First-Line Treatments in NSCLC DURHAM, N.C.–(BUSINESS WIRE)– GeneCentric Therapeutics, a company…
Read More

WRAL TechWire Interview with GeneCentric CEO About Recent Company Accomplishments

December 20, 2021
GeneCentric CEO Michael Milburn discusses recent company accomplishments and the year ahead, as well as and current trends in biotech and pharma with WRAL TechWire. Read More
Read More
1 2 3 … 5
Publications & Presentations

  • Year Published

  • Indication / Platform Functionality

AACR Pancreas: Purity independent subtyping of tumor (PurIST): real-world data validation of a pancreatic ductal adenocarcinoma (PDAC) gene expression classifier and its prognostic implications

September 17, 2022

Distinct predictive immunogenomic profiles of response to immune checkpoint inhibitors and IL2: a real-world evidence study of patients with advanced renal cancer

August 30, 2022

Mesenchymal gene expression subtyping analysis for early-stage human papillomavirus-negative head and neck squamous cell carcinoma reveals prognostic and predictive applications

June 6, 2022

ASCO: Detailed immunogenomic analysis of high dose IL-2 pharmacodynamic effects: A benchmark for next-generation IL-2-based immunotherapies

June 3, 2022

AUA: Frequency of fibroblast growth factor receptor alterations and association with bacillus Calmette-Guérin outcomes in a real-world genomic analysis of high-risk non-muscle-invasive bladder cancer (GARNER) study

May 16, 2022

AACR: Prognostic and predictive applications from mesenchymal gene expression subtype analysis for early-stage, HPV(-) head and neck squamous cell. carcinoma

April 11, 2022

LENS – Landscape of effective neoantigens software

April 5, 2022

AACR Pancreas: Initial retrospective analysis of mechanisms of FOLFIRINOX resistance using clinical and molecular data from the Know Your Tumor (KYT) pancreatic ductal adenocarcinoma (PDAC) cohort

September 29, 2021

Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience

July 26, 2021

ASCO: The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: A phase 2 study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma

June 4, 2021
1 2 3 4
Events

  • Year of Event

8th Annual Biomarker & Companion Diagnostics Conference – Feb. 8-9, 2023 | San Diego, CA

Date of Event: February 8, 2023
GeneCentric is a proud sponsor of the 8th Annual MarketsandMarkets Biomarker & Companion Diagnostics Conference to be held February 8-9, 2023 in San Diego, CA. Experts from academia and industry will present…
Read More